Tuesday , October 16 2018
Home / Humble student of the markets / Cam Hui / Nervous about FANGS? Here is a washed-out high beta opportunity

Nervous about FANGS? Here is a washed-out high beta opportunity

Summary:
Get more articles like thisBack to full articleAre you getting nervous about the FANG stocks? The debut of the FANG+ futures contract may mark a top for this group, as it presents an easy vehicle for hedgers to short these high beta stocks. But don’t despair, consider this chart of the relative performance of a high beta group that is washed-out, and may present an opportunity for investors and traders who missed out on the FANG move.  Would you buy this? Thought about Biotechs lately? The mystery chart is the relative performance of Biotech stocks (IBB) against the market. As the chart shows, the group is testing a key relative support zone when compared to the market. Unless the outlook deteriorates significantly, relative downside risk appears to be limited. There are a couple

Topics:
Cam Hui considers the following as important: , ,

This could be interesting, too:

Arathur Stephen writes Bitcoin Price Rallies Following Tether Sell-Off

Vladimir Vyun writes Pennant on Chart of Gold Gives Hopes to Bulls

Andriy Moraru writes Commodities Technical Analysis, October 15th — October 19th

Barry Ritholtz writes RIP: Paul Desmond of Lowry’s Research

Are you getting nervous about the FANG stocks? The debut of the FANG+ futures contract may mark a top for this group, as it presents an easy vehicle for hedgers to short these high beta stocks. But don’t despair, consider this chart of the relative performance of a high beta group that is washed-out, and may present an opportunity for investors and traders who missed out on the FANG move.
 

Nervous about FANGS? Here is a washed-out high beta opportunity

Would you buy this?

Thought about Biotechs lately?

The mystery chart is the relative performance of Biotech stocks (IBB) against the market. As the chart shows, the group is testing a key relative support zone when compared to the market. Unless the outlook deteriorates significantly, relative downside risk appears to be limited.

There are a couple of reasons to consider the Biotech stocks. First, the group is experiencing a bullish breadth divergence. IBB is a cap weighted ETF, which means that the largest capitalization stocks dominate the performance of that security. By contrast, the equal weight XBI Biotech ETF is performing much better.
 

Nervous about FANGS? Here is a washed-out high beta opportunity

There is also fundamental support for this group. The Morningstar fair value estimate shows that Biotech stocks are about 9% undervalued.
 

Nervous about FANGS? Here is a washed-out high beta opportunity

In conclusion, here is a high-beta group that is undervalued and washed-out. What more could anyone ask for?

About Cam Hui
Cam Hui
Cam Hui has been professionally involved in the financial markets since 1985 in a variety of roles, both as an equity portfolio manager and as a sell-side analyst. He graduated with a degree in Computer Science from the University of British Columbia in 1980 and obtained his CFA Charter in 1989. He is left & right brained modeler of quantitative investment systems. Blogs at Humble Student of the Markets.

Leave a Reply

Your email address will not be published. Required fields are marked *